Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1956 1
1957 1
1958 1
1960 2
1961 8
1962 4
1963 1
1964 2
1967 1
1968 2
1969 1
1970 5
1971 3
1972 7
1973 4
1974 6
1975 4
1976 2
1977 3
1978 4
1979 3
1980 9
1981 9
1982 9
1983 11
1984 18
1985 10
1986 11
1987 8
1988 13
1989 13
1990 21
1991 6
1992 17
1993 13
1994 7
1995 11
1996 12
1997 12
1998 15
1999 15
2000 10
2001 11
2002 16
2003 11
2004 11
2005 12
2006 12
2007 17
2008 13
2009 20
2010 13
2011 19
2012 14
2013 14
2014 18
2015 14
2016 14
2017 13
2018 13
2019 28
2020 46
2021 40
2022 32
2023 6
Text availability
Article attribute
Article type
Publication date

Search Results

679 results
Results by year
Filters applied: . Clear all
Page 1
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T. Kostine M, et al. Among authors: calabrese lh. Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23. Ann Rheum Dis. 2021. PMID: 32327425 Free PMC article.
Moving towards personalized treatments of immune-related adverse events.
Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L. Esfahani K, et al. Among authors: calabrese l. Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. doi: 10.1038/s41571-020-0352-8. Epub 2020 Apr 3. Nat Rev Clin Oncol. 2020. PMID: 32246128 Review.
Classification of GLOSSECTOMIES: Proposal for tongue cancer resections.
Ansarin M, Bruschini R, Navach V, Giugliano G, Calabrese L, Chiesa F, Medina JE, Kowalski LP, Shah JP. Ansarin M, et al. Among authors: calabrese l. Head Neck. 2019 Mar;41(3):821-827. doi: 10.1002/hed.25466. Epub 2019 Jan 2. Head Neck. 2019. PMID: 30600861 Free PMC article.
Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing.
Wilson MR, O'Donovan BD, Gelfand JM, Sample HA, Chow FC, Betjemann JP, Shah MP, Richie MB, Gorman MP, Hajj-Ali RA, Calabrese LH, Zorn KC, Chow ED, Greenlee JE, Blum JH, Green G, Khan LM, Banerji D, Langelier C, Bryson-Cahn C, Harrington W, Lingappa JR, Shanbhag NM, Green AJ, Brew BJ, Soldatos A, Strnad L, Doernberg SB, Jay CA, Douglas V, Josephson SA, DeRisi JL. Wilson MR, et al. Among authors: calabrese lh. JAMA Neurol. 2018 Aug 1;75(8):947-955. doi: 10.1001/jamaneurol.2018.0463. JAMA Neurol. 2018. PMID: 29710329 Free PMC article.
Central nervous system vasculitis: advances in diagnosis.
Hajj-Ali RA, Calabrese LH. Hajj-Ali RA, et al. Among authors: calabrese lh. Curr Opin Rheumatol. 2020 Jan;32(1):41-46. doi: 10.1097/BOR.0000000000000676. Curr Opin Rheumatol. 2020. PMID: 31652165 Review.
Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination.
Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME, Brodavka M, Cohen Y, Abu-Much A, Abu Elhija M, Bridgewood C, Langevitz P, McLorinan J, Bragazzi NL, Marzo-Ortega H, Lidar M, Calabrese C, Calabrese L, Vital E, Shoenfeld Y, Amital H, McGonagle D. Watad A, et al. Among authors: calabrese l. Vaccines (Basel). 2021 Apr 29;9(5):435. doi: 10.3390/vaccines9050435. Vaccines (Basel). 2021. PMID: 33946748 Free PMC article.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M. Winthrop KL, et al. Among authors: calabrese lh. Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S21-S40. doi: 10.1016/j.cmi.2018.02.002. Epub 2018 Feb 12. Clin Microbiol Infect. 2018. PMID: 29447987 Free article. Review.
679 results